Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
06/2012
06/07/2012WO2012047629A3 Selective removal of age-modified cells for treatment of ather0sclerosis
06/07/2012WO2012033353A9 Sesterterpene compounds and use thereof
06/07/2012WO2012028310A3 Compositions comprising a taxane for coating medical devices
06/07/2012WO2012004258A9 Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
06/07/2012WO2011152662A3 Ptd-uqcrb fusion polypeptide, and pharmaceutical composition for preventing and treating ischemic diseases, containing same
06/07/2012US20120142781 Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States
06/07/2012US20120142778 Microbiological method for synthesizing cinnamoyl amide derivatives of amino acids
06/07/2012US20120142776 Methods and compositions for inducing physiological hypertrophy
06/07/2012US20120142768 Formulations including amiodarone and salts thereof and methods of their manufacture and use
06/07/2012US20120142766 Substituted 1,3-dioxanes and their uses
06/07/2012US20120142758 Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
06/07/2012US20120142751 Methods for the production of biliverdin
06/07/2012US20120142745 Novel phenyl oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142740 Novel alkene derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142739 Novel oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142736 Novel pyridine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142735 Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]- 1h-indol-3-yl]-methanones
06/07/2012US20120142734 Methods for treating tumors with thalidomide
06/07/2012US20120142733 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2
06/07/2012US20120142732 Heteroaryls and uses thereof
06/07/2012US20120142729 KAT ll INHIBITORS
06/07/2012US20120142728 Chemical compound and its use
06/07/2012US20120142726 Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
06/07/2012US20120142723 Ace2 activator compounds and methods of use thereof
06/07/2012US20120142716 4-pyrimidinesulfamide derivative
06/07/2012US20120142709 Substituted pyridinone-pyridinyl compounds
06/07/2012US20120142708 Substituted pyridine urea compounds
06/07/2012US20120142696 Substituted indole/indazole-pyrimidinyl compounds
06/07/2012US20120142691 Picolinamide derivatives as ttx-s blockers
06/07/2012US20120142690 Substituted piperidines
06/07/2012US20120142689 Serotonin reuptake inhibitors
06/07/2012US20120142685 Organic compounds
06/07/2012US20120142680 Heteroalkyl linked pyrimidine derivatives
06/07/2012US20120142677 Pyrrolidine Compounds Which Modulate The CB2 Receptor
06/07/2012US20120142671 Benzamides and nicotinamides as syk modulators
06/07/2012US20120142666 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor
06/07/2012US20120142664 Novel benzyl azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142663 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142662 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142661 Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142659 Compounds and their use as ikach blockers
06/07/2012US20120142642 Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142640 Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators
06/07/2012US20120142639 Oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142638 Combination of organic compounds
06/07/2012US20120142636 Novel glucokinase activators and methods of using same
06/07/2012US20120142633 Methylpyrrolopyridinecarboxamides
06/07/2012US20120142632 Diagnostic and prognostic assay
06/07/2012US20120142620 Core 2 glcnac-t inhibitors
06/07/2012US20120142618 Ketogenic saccharides
06/07/2012US20120142615 Methods related to the treatment of neurodegenerative and inflammatory conditions
06/07/2012US20120142612 Cytokine protein family
06/07/2012US20120142610 Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
06/07/2012US20120142595 Tissue protective peptides and uses thereof
06/07/2012US20120142589 Tissue-protective cytokines for the protection, restoration and enhancement of responsive cells, tissues and organs
06/07/2012US20120142582 Combination of Dopamine Agonists Plus First Phase Secretagogues for the Treatment of Metabolic Disorders
06/07/2012US20120141618 Process for preparing integral olive juice, using this process to obtain the composition and its application in the field of cosmetics and nutrition
06/07/2012US20120141612 Composition and Method for Improving Vascular Health
06/07/2012US20120141586 Thrombin receptor antagonist and clopidogrel fixed dose tablet
06/07/2012US20120141573 Cell Lines That Secrete Anti-Angiogenic Antibody-Scaffolds and Soluble Receptors and Uses Thereof
06/07/2012US20120141563 Pharmaceutical composition including a dha ester to be administered parenterally
06/07/2012US20120141561 Nanoparticulate candesartan cilexitil compositions, process for the preparation thereof and pharmaceutical compositions containing them
06/07/2012US20120141558 Alginate-based nanofibers and related scaffolds
06/07/2012US20120141547 Methods of making cell sheets, tissue sheets and tissue engineered blood vessels
06/07/2012US20120141538 Modulators of the cx3cri receptor and therapeutic uses thereof
06/07/2012US20120141499 Specific binding agents of human angiopoietin-2
06/07/2012US20120141490 Antibodies That Bind Selectively To P25 And Uses Therefor
06/07/2012US20120141489 Hypoxia Induced Mitogenic Factor
06/07/2012US20120141466 Composition and method for treatment of reperfusion injury and tissue damage
06/07/2012US20120141464 Binding member for gm-csf receptor
06/07/2012US20120141461 Compositions and methods for diagnosing and treating fibrotic disorders
06/07/2012US20120141457 Lateral Flow Immunoassay for Complement Activation and Methods of Use for Point-of-Care Assessment of Complement-Associated Disorders
06/07/2012US20120141451 Fibroblast growth factor receptor-derived peptides binding to ncam
06/07/2012US20120141450 Risk markers for cardiovascular disease
06/07/2012US20120141449 Albumin Fusion Proteins
06/07/2012US20120141446 Oral Nutritional Supplement Delivery System
06/07/2012US20120141442 Means and methods for counteracting, delaying and/or preventing adverse energy metabolism switches in heart disease
06/07/2012US20120141438 Cardiac muscle repair or regeneration using bone marrow-derived stem cells
06/07/2012US20120141437 Cardiac Muscle Regeneration Using Mesenchymal Stem Cells
06/07/2012US20120141435 Use of olive leaf extracts in a pharmaceutical composition for inducing angiogenesis and vasculogenesis
06/07/2012US20120141424 Materials and Methods for the Treatment of Hypertension
06/07/2012US20120141419 Biodegradable Linkers for Molecular Therapies
06/07/2012US20120141416 Multimeric peptide conjugates and uses thereof
06/07/2012US20120141415 Albumin Fusion Proteins
06/07/2012US20120141379 Microspheres for active embolization
06/07/2012US20120138506 Methods of treatment and pharmaceutical composition
06/07/2012CA2820622A1 Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
06/07/2012CA2819854A1 Nitric oxide treatments
06/07/2012CA2819673A1 Novel pyridine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012CA2819671A1 Novel oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012CA2819648A1 Substituted purine and 7-deazapurine compounds
06/07/2012CA2819619A1 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012CA2819613A1 Novel alkene derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012CA2819609A1 Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012CA2819504A1 Anti-bradykinin b2 receptor (bkb2r) monoclonal antibody
06/07/2012CA2819460A1 Orally disintegrating tablet
06/07/2012CA2812348A1 Egfr antagonist for the treatment of heart disease
06/07/2012CA2804129A1 Manufacturing method for dried earthworm powder
06/06/2012EP2460537A1 Methods for treating conditions associated with MASP-2 dependent complement activation
06/06/2012EP2460525A1 Elastin stabilization of connective tissue
1 ... 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 ... 1595